Parnell Pharmaceuticals Holdings Ltd
PARNF · OTC
12/31/2016 | 9/30/2016 | 6/30/2016 | 12/31/2015 | |
|---|---|---|---|---|
| Revenue | $7,338 | $4,550 | – | $4,052 |
| % Growth | 61.3% | – | – | – |
| Cost of Goods Sold | $2,638 | $2,689 | – | $2,514 |
| Gross Profit | $4,700 | $1,861 | – | $1,538 |
| % Margin | 64% | 40.9% | – | 38% |
| R&D Expenses | $331 | $402 | – | $230 |
| G&A Expenses | $2,518 | $3,415 | – | $4,328 |
| SG&A Expenses | $5,299 | $6,995 | – | $9,273 |
| Sales & Mktg Exp. | $2,781 | $3,580 | – | $4,945 |
| Other Operating Expenses | $0 | $0 | – | $0 |
| Operating Expenses | $5,631 | $7,398 | – | $9,503 |
| Operating Income | -$931 | -$5,537 | – | -$7,965 |
| % Margin | -12.7% | -121.7% | – | -196.6% |
| Other Income/Exp. Net | -$2,179 | -$569 | – | -$355 |
| Pre-Tax Income | -$3,110 | -$6,106 | – | -$8,320 |
| Tax Expense | -$2 | $0 | – | $0 |
| Net Income | -$3,108 | -$6,106 | – | -$8,320 |
| % Margin | -42.4% | -134.2% | – | -205.3% |
| EPS | 0 | 0 | – | 0 |
| % Growth | – | – | – | – |
| EPS Diluted | 0 | 0 | – | 0 |
| Weighted Avg Shares Out | 0 | 0 | – | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | – | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | – | $0 |
| Interest Expense | $2,179 | $569 | – | $355 |
| Depreciation & Amortization | $0 | $0 | – | $0 |
| EBITDA | -$931 | -$5,537 | – | -$7,965 |
| % Margin | -12.7% | -121.7% | – | -196.6% |